Who is sponsoring NCT00554658?

NCT00554658 is sponsored by University of Regensburg.

What condition does NCT00554658 study?

NCT00554658 studies Schizophrenia.

What is the status of NCT00554658?

NCT00554658 is currently COMPLETED.

Last reviewed 2011-10-21 · How we verify

Quetiapine Induced Neuroplasticity in Schizophrenic Patients: A Combined Transcranial Magnetic Stimulation (TMS) and Voxel-based Morphometry (VBM) Study

NCT00554658 Phase 4 COMPLETED

Aim of the study is to assess the effect of quetiapine treatment in neuroleptic naive, first-episode schizophrenic patients on aspects of functional and structural neuroplasticity assessed by means of transcranial magnetic stimulation and voxel-based morphometry. Main outcome measure is a change in gray matter density under quetiapine treatment from baseline to steady-state-treatment after 3 weeks.

Details

Lead sponsor	University of Regensburg
Phase	Phase 4
Status	COMPLETED
Enrolment	30
Start date	2008-03
Completion	2011-03

Conditions

Schizophrenia

Interventions

Quetiapine

Primary outcomes

Change of structural neuroplasticity (i.e. change in gray matter density) under treatment with quetiapine assessed by voxel-based morphometry. — 3 weeks

Countries

Germany